查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863372

基因融合檢測市場按技術、檢體類型、應用和最終用戶分類－2025-2032年全球預測

Gene Fusion Testing Market by Technology, Sample Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，基因融合檢測市場將成長至 12.5788 億美元，複合年成長率為 12.76%。

關鍵市場統計數據
基準年 2024 4.8095億美元
預計年份：2025年 5.4132億美元
預測年份 2032 1,257,880,000 美元
複合年成長率 (%) 12.76%

基因融合檢測與臨床路徑、轉化研究以及診斷生態系統中相關人員決策的相關性：一個簡明策略框架。

基因融合檢測已成為現代分子診斷和轉化研究的核心組成部分，重塑了腫瘤學、血液學和罕見疾病等臨床診療路徑中的決策過程。檢測方法設計和分析流程的進步，已將檢測方式從單基因和細胞遺傳學方法轉變為整合分子譜分析，從而揭示可靶向的融合基因、抗藥性機制和疾病亞型。隨著標靶治療在臨床上的廣泛應用，精準識別基因融合對於患者篩選、治療監測以及精準醫療試驗的入組合格至關重要。

本摘要對技術演進、監管和貿易影響、細分市場趨勢、區域應用模式、競爭動態以及對行業相關人員的建議進行了摘要分析。它基於實驗室工作流程最佳化、定序方法興起以及檢體處理限制與檢測靈敏度之間相互作用的實證數據，為決策者提供了一個策略框架下的概覽。本概要重點闡述了哪些領域的投資、合作和營運重點能夠顯著提升臨床效用和商業性吸引力。

本文重點介紹了診斷實驗室、臨床中心、製藥開發公司和研究機構之間的綜合測試策略和多學科合作如何重新定義從發現到臨床實施的路徑，為讀者提供了一個在科學技術能力與市場和監管現實的交匯處創造創新和競爭優勢機會的實用觀點。

技術融合、監管政策明確化和臨床證據將如何加速基因融合檢測的標準化和臨床應用？

基因融合檢測領域已發生變革性轉變，這主要得益於技術融合、監管成熟和不斷湧現的臨床證據。過去以細胞遺傳學檢測和單一分析方法為主，而如今則更重視結合正交驗證方法和高解析度分析的多模態策略。次世代定序技術促進了這項轉變，不僅能夠廣泛檢測標準和新型融合基因，還能整合實驗室工作流程，並縮短檢測時間。

同時，融合檢測的臨床效用正從最初的診斷分類擴展到治療方案選擇、微量殘存疾病評估以及伴隨診斷的開發。檢體處理技術的進步也促進了這一發展，包括改進從福馬林固定、石蠟包埋組織中提取核酸的方法以及最佳化循環核酸的血漿通訊協定，這些進步共同提高了檢測的產量，並擴大了非侵入性檢測的合格患者範圍。

市場進入促進因素，例如更完善的報銷框架和實驗室自建檢測 (LDT) 和體外診斷 (IVD) 的明確監管路徑，正在推動醫院和獨立實驗室採用先進的檢測方法。此外，隨著藥物研發越來越依賴分子特徵明確人群的招募，診斷開發商和製藥公司之間的合作也不斷加強。總而言之，這些變化標誌著一個成熟的生態系統正在形成，在這個生態系統中，技術能力、臨床需求和商業性獎勵相互協調，加速基因融合檢測的標準化和規模化應用。

評估2025年美國關稅對基因融合檢測價值鏈的供應鏈、籌資策略和業務永續營運的影響

美國將於2025年實施關稅，這給全球融合檢測供應鏈中的相關人員帶來了新的挑戰。由於成本結構的變化和供應風險評估的更新，採購團隊表示，試劑採購、設備購買和耗材供應流程都受到了更嚴格的審查。實驗室和製造商正在評估多種採購策略和庫存緩衝，以緩解短期採購波動，同時確保為患者提供持續的檢測服務。

除了採購之外，關稅環境也促使企業對區域製造地和分銷網路進行策略性重新評估。一些公司正在加快關鍵零件的在地化生產，或尋求與國內供應商建立合作關係，以降低跨境關稅風險。監管團隊也預計，由於零件替換，產品可能需要重新認證，這推動了品質保證、監管和供應鏈部門之間更緊密的合作。

臨床醫生和實驗室負責人強調，維持檢測效能和結果週轉時間是重中之重。因此，營運調整的重點是優先採用檢驗的替代方案和互換性測試，以避免中斷臨床工作流程。同時，銷售團隊正在與醫療機構和參考實驗室審查定價和合約模式，以便根據客戶談判和競爭環境來承擔或轉嫁成本影響。整體而言，關稅主導的環境正在迫使產業採取更具韌性和靈活性的姿態，強調供應鏈透明度、區域能力和跨職能協作，以確保患者照護的連續性。

針對特定領域的診斷和商業性洞察，重點介紹整個檢測過程中的技術差異、檢體限制、臨床應用和最終用戶工作流程要求。

深入了解特定細分領域的趨勢對於確定基因融合檢測領域的投資和發展重點至關重要。技術評估必須反映每種方法的獨特優點和限制：螢光原位雜合反應(FISH)、免疫組織化學 (IHC)、次世代定序(NGS) 和 RT-PCR。次世代定序本身又分為標靶基因panel檢測、轉錄組定序和全基因測序，每種方法在範圍、分析複雜性和基礎設施需求方面各不相同。每種技術途徑都需要不同的檢驗方法、生物資訊學流程和終端使用者培訓，以確保臨床層級的結果解讀和可重複性。

檢體類型對操作設計和檢測的可近性有顯著影響。基於血液的工作流程需要採用能夠保存循環核酸的血漿和血清處理通訊協定，而組織工作流程則必須同時考慮福馬林固定、石蠟包埋的樣本和冷凍組織，這兩種樣本在核酸完整性、週轉時間和組織病理學整合方面各有優劣。應用主導的細分錶明，血液學、腫瘤學和罕見疾病應用場景對靈敏度、特異性和報告粒度有著不同的臨床閾值要求。在血液學領域，白血病和淋巴瘤檢測有助於治療方法分層和微量殘存疾病評估，而乳癌、結直腸癌、肺癌和前列腺癌等腫瘤學應用則優先考慮檢測具有治療價值的融合基因和抗藥性機制。罕見疾病應用，包括發育障礙和神經肌肉疾病，通常需要更廣泛的轉錄組分析和專門的解讀框架。

終端用戶差異化進一步影響商業性策略和服務設計。院內和獨立診斷實驗室優先考慮的是檢測量最佳化和檢測方法標準化。醫院（包括住院部和門診部）優先考慮的是快速報告檢測結果並與電子健康記錄 (EHR) 系統整合。從生技公司到大型製藥企業，製藥公司尋求伴隨診斷合作夥伴和嚴格的分析檢驗，以支持臨床試驗。研究機構（包括學術實驗室和商業實驗室）推動早期發現和方法開發，這些成果可進入臨床研發流程。了解這些相互關聯的細分市場有助於更精準地確定產品功能、市場通路和合作模式的優先級，從而使技術能力與終端用戶的工作流程和結果解讀需求相匹配。

區域比較分析塑造了美洲、歐洲、中東和非洲以及亞太地區的採用趨勢、合作模式和營運策略。

區域趨勢對融合檢測相關人員的採納路徑、夥伴關係機會和營運重點有顯著影響。在美洲，廣泛的診斷實驗室網路以及臨床中心和藥物研發計畫之間的高度協作塑造了該地區的服務提供模式。該地區傾向於優先採用先進的定序方法，並建立與藥物研發時間表和法規結構相符的伴隨診斷。醫院、參考實驗室和產業合作夥伴之間的合作聯盟通常能夠進行多中心檢驗研究，並加速臨床應用。

歐洲、中東和非洲地區（EMEA）情況複雜多樣，既有高度集中的國家級參考實驗室系統，也有分散的醫院網路。各醫療系統的採購模式和報銷途徑差異巨大，而監管協調和跨境臨床合作正在推動某些市場採用新技術。該地區的相關人員通常致力於證明成本效益、臨床效用以及與不同醫療IT基礎設施基礎設施的互通性，以期獲得公立和私立醫療機構的認可。

全部區域基礎設施的快速投資以及政府對精準醫療舉措的大力支持，正推動學術研究和商業性檢測能力的雙雙成長。在多個市場，實驗室正在建立本地化生產能力，以拓展定序的服務並減少對進口的依賴。區域公共衛生重點和特定族群的基因組特徵也影響檢測方法的選擇和檢驗策略，從而推動個人化檢測方案的製定，以反映當地的臨床需求和檢體可用性。為了因應這些區域差異，差異化的合作模式和策略投資計畫對於最佳化市場准入、建立夥伴關係和服務交付至關重要。

競爭格局分析重點在於平台差異化、協同創新和策略夥伴關係，以推動臨床整合和市場滲透。

基因融合檢測領域的競爭格局由成熟的診斷公司、專業的定序平台提供者以及專注於檢測化學和生物資訊學的新興創新者共同構成​​。領先的診斷開發人員正致力於開發端到端解決方案，將經過檢驗的檢測方法與強大的資訊科學、監管文件以及為醫院和參考實驗室客戶量身定做的服務模式相結合。平台提供者則透過提高通量、提升讀取準確性以及與實驗室資訊管理系統無縫整合來不斷提升自身競爭力，從而最大限度地減少工作流程中斷。

同時，一些創新參與企業正透過轉錄組層級的方法和新型樣品製備化學技術，不斷突破檢測靈敏度和廣度的極限，從而能夠檢測複雜或罕見的融合事件。這些進展通常源自於學術合作或商業實驗室，之後才被應用於臨床實踐，凸顯了研究機構與商業機構之間建立策略聯盟的重要性。製藥公司透過委託進行分析檢驗研究和共同開發伴隨診斷試劑，繼續發揮關鍵的合作作用，以支持標靶治療計畫。

併購、策略聯盟和分銷協議是拓展全球業務、應對供應鏈脆弱性的常用方式。能夠有效結合強大的技術基礎、經臨床檢驗的效用和靈活的商業模式的公司，在與醫療系統和臨床實驗申辦者建立長期合作關係方面更具優勢。最終，那些在創新、嚴格的監管合規性、營運可靠性和明確的臨床療效證據之間取得平衡的企業，將獲得競爭優勢。

為組織機構提供切實可行的策略行動，以增強韌性、加速臨床應用並提升診斷和治療生態系統內的協作價值創造。

產業領導者應優先考慮一系列切實可行的舉措，以增強韌性、加速臨床應用並釋放融合檢測生態系統的新價值。首先，投資於模組化、檢驗的工作流程，使實驗室能夠逐步採用基於定序的檢測方法，從而降低准入門檻，同時保持分析的嚴謹性。這種方法有助於逐步升級並減少訓練阻力，從而促進醫院和獨立實驗室的廣泛應用。

其次，提高供應鏈透明度和多元化籌資策略可以降低關稅和供應中斷的風險。確保關鍵試劑的合格二級供應商，並探索區域製造夥伴關係，可以最大限度地減少前置作業時間的波動，保障檢測的連續性。與籌資策略並行，相關人員應建立健全的變更控制通訊協定，以便在不影響效能的前提下對替代零件進行預先認證。

第三，企業應深化與藥物研發企業和臨床網路的合作，促進伴隨診斷的共同開發和前瞻性檢驗研究，以證明其臨床效用。將檢測設計與治療開發平臺結合，可以加快患者獲得標靶治療的速度，並增強商業性價值提案。最後，增加對臨床醫師教育和標準化報告範本的投入，可以改善檢測結果的解讀，增強臨床醫師的信心，並促進檢測結果順利融入治療決策過程。綜合運用這些措施，將使企業能夠靈活應對外部衝擊，同時掌握技術創新和不斷變化的臨床需求所帶來的機會。

採用透明、多方面的研究途徑，結合相關利益者訪談、技術文獻和營運案例研究，以支持可操作的研究結果和建議。

本研究綜合分析採用多方面方法，從技術、臨床和商業性觀點進行三角驗證。主要資料來源包括實驗室主任、分子病理學家、採購人員和臨床試驗相關人員的結構化訪談，以及與檢測方法開發人員和平台提供者的面對面諮詢。次要分析涵蓋同儕審查文獻、監管指導文件、技術白皮書和產品手冊，檢驗分析方法和監管方面的考量。在適用情況下，來自實驗室的匿名營運案例研究為工作流程實施和檢驗中遇到的挑戰提供了真實案例背景。

透過對技術性能特徵、檢體處理通訊協定和最終用戶需求進行系統性的交叉檢驗，確保了分析的嚴謹性。調查方法優先考慮同儕審查的證據和關鍵相關人員的證詞，以確保建議既體現科學有效性，又具有實際操作可行性。對區域法規環境和報銷環境的考量為區域洞察奠定了基礎，而供應鏈評估則整合了採購數據和供應商訪談，以評估薄弱環節和緩解措施。

我們認知到任何綜合分析都存在固有的局限性，包括不同實驗室報告標準的差異以及區域監管解釋的差異。為了克服這些限制，我們的方法強調資料來源的透明度、對假設的明確記錄，以及提供詳細的調查方法，包括訪談指南、納入標準和檢驗查核點。這種方法使相關人員能夠對基礎證據充滿信心，同時又能根據自身俱體的操作環境調整研究結果。

關於如何協調技術能力、營運韌性和合作夥伴關係，以充分發揮基因融合檢測的臨床潛力，得出綜合策略結論。

基因融合檢測技術的成熟是技術創新、臨床需求以及診斷開發商、醫療系統和製藥合作夥伴之間戰略合作共同作用的結果。隨著基於定序的方法日益普及和檢體處理技術的進步，將可靠的融合基因檢測納入常規診斷的機會從未如此清晰。然而，要充分發揮這一潛力，需要檢驗的工作流程、穩健的供應鏈以及對合作證據產生的持續投入，以證明其在不同患者群體中的臨床效用。

那些現在就將檢測設計與終端用戶工作流程相匹配、實現供應鏈網路多元化並與治療藥物開發商建立戰略夥伴關係的相關人員，將更有利於確保營運的連續性，同時充分利用科學進步。不斷變化的監管環境和報銷體系重視清晰的證據和跨部門合作，因此，儘早與臨床和監管相關人員開展合作將成為一項競爭優勢。總之，基因融合檢測生態系統已做好持續整合臨床應用的準備，而那些推動技術、商業性和營運一體化策略的機構將主導從發現到改善患者療效的下一階段。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 採用多重次世代定序檢測方法同時檢測腫瘤患者的基因融合
  • 將液態生物檢體平台整合到癌症篩檢計畫中，用於非侵入性基因融合檢測。
  • 標靶治療的擴展推動了個人化醫療中對精確基因融合分析的需求。
  • 開發基於人工智慧的生物資訊流程，以提高臨床診斷中基因融合識別的準確性
  • 實驗室開發的檢測方法不斷發展，可提供快速基因融合分析，從而在診療現場為腫瘤決策提供支援。
  • 診斷公司和製藥公司之間的合作正在擴大，以共同開發基於融合基因的治療性生物標記。
  • 新型基因融合檢測套件獲監理機關核准，加速進入新興市場
  • RNA多重PCR檢測在固態腫瘤中罕見融合轉錄本的全面檢測中的應用日益廣泛
  • 自動化樣本到報告平台的出現將縮短臨床實驗室基因融合分析的周轉時間
  • 推動社區醫院基因融合檢測分散式檢查網路擴張的投資趨勢

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 基因融合檢測市場（依技術分類）

  • 螢光原位雜合反應
  • 免疫組織化學
  • 次世代定序
    • 標靶次世代定序
    • 轉錄定序
    • 全基因測序
  • 逆轉錄聚合酵素鏈鎖反應

9. 依檢體類型分類的基因融合檢測市場

  • 血
    • 電漿
    • 血清
  • 組織
    • 福馬林固定石蠟包埋
    • 新鮮冷凍組織

第10章 基因融合檢測市場（依應用領域分類）

  • 血液學
    • 白血病
    • 淋巴瘤
  • 腫瘤學
    • 乳癌
    • 大腸直腸癌
    • 肺癌
    • 攝護腺癌
  • 罕見疾病
    • 發展障礙
    • 神經肌肉疾病

第11章 基因融合檢測市場（依最終用戶分類）

  • 診斷實驗室
    • 醫院檢查室
    • 獨立檢驗機構
  • 醫院
    • 住院設施
    • 門診部
  • 製藥公司
    • 生技公司
    • 大型製藥公司
  • 研究所
    • 學術機構
    • 私人研究機構

第12章 基因融合檢測市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 基因融合檢測市場（依群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國基因融合檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Illumina, Inc.
    • F. Hoffmann-La Roche Ltd
    • Agilent Technologies, Inc.
    • QIAGEN NV
    • Bio-Rad Laboratories, Inc.
    • NanoString Technologies, Inc.
    • BGI Genomics Co., Ltd.
    • Foundation Medicine, Inc.
    • Archer DX, Inc.
Product Code: MRR-2E76C3E47FBF

The Gene Fusion Testing Market is projected to grow by USD 1,257.88 million at a CAGR of 12.76% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 480.95 million
Estimated Year [2025] USD 541.32 million
Forecast Year [2032] USD 1,257.88 million
CAGR (%) 12.76%

Concise strategic framing of gene fusion testing relevance to clinical pathways, translational research, and stakeholder decision-making in diagnostic ecosystems

Gene fusion testing has emerged as a pivotal component of modern molecular diagnostics and translational research, reshaping clinical decision-making across oncology, hematology, and rare disease pathways. Advances in assay design and analytic pipelines have shifted testing from single-gene or cytogenetic approaches toward integrated molecular profiles that reveal actionable fusions, resistance mechanisms, and disease subtypes. As the clinical adoption of targeted therapies expands, precise identification of gene fusions has become essential for patient selection, therapeutic monitoring, and eligibility for precision medicine trials.

This summary synthesizes technological evolution, regulatory and trade influences, segment-level dynamics, regional adoption patterns, competitive movements, and recommendations for industry stakeholders. It draws on evidence of laboratory workflow optimization, the rising role of sequencing-based modalities, and the interplay between sample handling constraints and assay sensitivity. The goal is to provide decision-makers with a concentrated, strategically framed narrative that highlights where investment, partnership, and operational focus can materially improve clinical utility and commercial traction.

Throughout the document, emphasis is placed on how integrated testing strategies and cross-disciplinary collaboration between diagnostic laboratories, clinical centers, pharmaceutical developers, and research institutions are redefining pathways from discovery to clinical implementation. In doing so, readers will gain an actionable perspective on where scientific capability intersects with market and regulatory realities to create opportunities for innovation and competitive differentiation.

How technological convergence, regulatory clarity, and clinical evidence are accelerating standardization and broader clinical adoption of gene fusion testing

The landscape for gene fusion testing has undergone transformative shifts driven by technological convergence, regulatory maturation, and evolving clinical evidence. Historically dominated by cytogenetic and single-analyte assays, the field now favors multi-modal strategies that combine orthogonal confirmation with high-resolution profiling. Next-generation sequencing has catalyzed this transition, enabling broader detection of canonical and novel fusions while allowing laboratories to consolidate workflows and reduce time-to-result variability.

Concurrently, the clinical utility of fusion detection has expanded beyond initial diagnostic categorization to include therapy selection, minimal residual disease evaluation, and companion diagnostic development. This evolution is complemented by improvements in sample processing, such as enhanced nucleic acid extraction from formalin-fixed paraffin embedded tissue and optimized plasma protocols for circulating nucleic acids, which collectively increase assay yield and broaden patient eligibility for noninvasive testing.

Market access drivers, including more nuanced reimbursement frameworks and clearer regulatory pathways for laboratory-developed tests and in vitro diagnostics, have supported the adoption of advanced assays in hospital-based and independent laboratories alike. Partnerships between diagnostic developers and pharmaceutical companies have also intensified as drug development increasingly predicates enrollment on molecularly defined populations. Taken together, these shifts indicate a maturing ecosystem where technological capability, clinical need, and commercial incentives align to accelerate the standardization and scaling of gene fusion testing.

Assessment of the 2025 United States tariff impacts on supply chains, procurement strategies, and operational resilience within gene fusion testing value chains

The introduction of United States tariffs in 2025 has created a new layer of complexity for stakeholders operating in global supply chains for gene fusion testing. Procurement teams report increased scrutiny of reagent sourcing, instrument purchases, and consumable pipelines as cost profiles shift and supply risk assessments are updated. Laboratories and manufacturers are evaluating dual-sourcing strategies and inventory buffers to mitigate near-term procurement volatility while maintaining continuity of testing services for patients.

Beyond procurement, the tariff environment has prompted strategic re-evaluation of regional manufacturing footprints and distribution networks. Some companies have accelerated localization of critical component manufacturing or pursued partnerships with domestic suppliers to reduce exposure to cross-border duties. Regulatory teams are also anticipating potential product requalification needs associated with component substitutions, driving closer collaboration between quality assurance, regulatory affairs, and supply chain functions.

Clinicians and laboratory directors emphasize that maintaining assay performance and turnaround times remains paramount; therefore, operational adjustments prioritize validated alternatives and compatibility testing to avoid disruptions to clinical workflows. In parallel, commercial teams are recalibrating pricing and contracting models with health systems and reference laboratories to absorb or pass through cost impacts based on customer negotiations and competitive dynamics. Overall, the tariff-driven environment is forcing a more resilient and flexible industry posture, with an emphasis on supply chain transparency, localized capabilities, and cross-functional coordination to sustain uninterrupted patient care.

Segment-focused diagnostic and commercial insights highlighting technology distinctions, sample constraints, clinical applications, and end-user workflow requirements across the testing continuum

A granular appreciation of segment-specific dynamics is essential for targeting investment and development priorities within the gene fusion testing domain. When examining technology, assessments need to reflect the distinct advantages and constraints of Fluorescence In Situ Hybridization, Immunohistochemistry, Next Generation Sequencing, and RT-PCR, noting that Next Generation Sequencing itself comprises targeted panels, transcriptome sequencing, and whole genome sequencing approaches that vary in breadth, analytical complexity, and infrastructure requirements. Each technological path demands different validation approaches, bioinformatics pipelines, and end-user training to ensure clinical-grade interpretation and reproducibility.

Sample type considerations strongly influence operational design and test accessibility. Blood-based workflows require protocols for plasma and serum processing that preserve circulating nucleic acids, while tissue workflows must account for formalin-fixed paraffin embedded specimens and fresh frozen tissue, each presenting trade-offs in nucleic acid integrity, turnaround, and histopathology integration. Application-driven segmentation highlights that hematology, oncology, and rare disease use cases impose divergent clinical thresholds for sensitivity, specificity, and reporting granularity. Within hematology, testing for leukemia and lymphoma informs therapeutic stratification and minimal residual disease assessment, whereas oncology applications in breast, colorectal, lung, and prostate cancers prioritize the detection of actionable fusions and mechanisms of resistance. Rare disease applications, including developmental disorders and neuromuscular conditions, often require broader transcriptomic interrogation and specialized interpretation frameworks.

End-user differentiation further shapes commercial approaches and service design. Diagnostic laboratories, both hospital-based and independent, emphasize throughput optimization and assay standardization; hospitals, across inpatient facilities and outpatient clinics, value rapid turnaround and integration with electronic health records; pharmaceutical companies, spanning biotechnology firms and larger pharma organizations, seek companion diagnostic partnerships and rigorous analytical validation to support clinical trials; and research institutions, including academic centers and private research laboratories, drive early-stage discovery and method development that can translate into clinical pipelines. Understanding these interconnected segments enables more precise prioritization of product features, go-to-market channels, and collaborative models that align technical capability with end-user workflows and interpretive needs.

Comparative regional dynamics that shape adoption, partnership models, and operational strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific jurisdictions

Regional dynamics materially influence adoption pathways, partnership opportunities, and operational priorities for gene fusion testing stakeholders. In the Americas, service delivery models are shaped by an extensive network of diagnostic laboratories and a high degree of integration between clinical centers and pharmaceutical development programs. This region tends to prioritize rapid implementation of advanced sequencing modalities and the establishment of companion diagnostics that align with drug development timelines and regulatory frameworks. Collaborative consortia between hospitals, reference labs, and industry partners frequently enable multi-site validation studies and accelerated clinical adoption.

In Europe, Middle East & Africa, the landscape is heterogeneous, with pockets of highly centralized national reference laboratory systems coexisting alongside decentralized hospital networks. Regulatory harmonization efforts and cross-border clinical collaborations are driving wider adoption in select markets, while health system procurement models and reimbursement pathways vary significantly. Stakeholders in this region often focus on demonstrating cost-effectiveness, clinical utility, and interoperability with diverse health IT infrastructures to gain adoption across public and private providers.

Across Asia-Pacific, rapid infrastructure investment and strong government support for precision medicine initiatives have catalyzed growth in both academic research and commercial testing capacity. Laboratories in several markets are scaling sequencing-based services and developing localized manufacturing capabilities to reduce reliance on imports. Regional public health priorities and population-specific genomic characteristics also shape test selection and assay validation strategies, prompting tailored approaches that reflect local clinical needs and sample availability. These regional nuances necessitate differentiated engagement models and strategic investment plans to optimize market entry, partnerships, and service delivery.

Competitive landscape analysis emphasizing platform differentiation, collaborative innovation, and strategic partnerships that drive clinical integration and market traction

Competitive activity in the gene fusion testing arena is defined by a mix of established diagnostic companies, specialized sequencing platform providers, and emerging innovators focused on assay chemistry and bioinformatics. Leading diagnostic developers are investing in end-to-end solutions that combine validated assays with robust informatics, regulatory documentation, and service models tailored to hospital and reference laboratory customers. Platform providers continue to differentiate through throughput capabilities, read accuracy, and seamless integration with laboratory information management systems to minimize workflow interruption.

At the same time, innovative entrants are pushing the boundaries of sensitivity and breadth through transcriptome-level approaches and novel library preparation chemistries that enable detection of complex or rare fusion events. These advancements often emerge from academic collaborations and private research labs before being adopted in clinical settings, underscoring the importance of strategic partnerships between research institutions and commercial entities. Pharmaceutical companies remain key collaborators, commissioning analytical validation studies and co-developing companion diagnostics to support targeted therapy programs.

Mergers, strategic alliances, and distribution agreements are common mechanisms for scaling global presence and addressing supply chain vulnerabilities. Companies that successfully combine strong technical platforms, validated clinical utility, and flexible commercial models are better positioned to secure long-term relationships with health systems and trial sponsors. Ultimately, competitive advantage accrues to organizations that balance innovation with regulatory rigor, operational reliability, and clear evidence of clinical impact.

Practical strategic actions for organizations to enhance resilience, accelerate clinical adoption, and strengthen collaborative value creation across diagnostic and therapeutic ecosystems

Industry leaders should prioritize a series of actionable initiatives to strengthen resilience, accelerate clinical adoption, and unlock new value across the gene fusion testing ecosystem. First, investing in modular, validated workflows that allow laboratories to adopt sequencing-based assays incrementally can lower barriers to entry while preserving analytical rigor. This approach facilitates stepwise upgrades and reduces training friction, enabling broader uptake among hospital-based and independent laboratories.

Second, strengthening supply chain transparency and diversifying sourcing strategies will mitigate tariff and disruption risks. Establishing qualified secondary suppliers for critical reagents and exploring regional manufacturing partnerships can minimize lead-time variability and protect assay continuity. Parallel to procurement strategies, stakeholders should institute robust change-control protocols that preemptively qualify alternative components without compromising performance.

Third, companies should deepen collaborations with pharmaceutical developers and clinical networks to co-develop companion diagnostics and prospective validation studies that demonstrate clinical utility. Aligning assay design with therapeutic development pipelines can accelerate patient access to targeted therapies and enhance the commercial value proposition. Finally, investing in clinician-facing education and standardized reporting templates will improve test interpretation, increase clinician confidence, and facilitate smoother integration into treatment decision pathways. These combined actions will position organizations to respond nimbly to external shocks while capturing opportunities created by technological innovation and evolving clinical demand.

Transparent multi-method research approach combining stakeholder interviews, technical literature, and operational case studies to underpin actionable insights and recommendations

This research synthesis is grounded in a multi-method approach designed to triangulate technical, clinical, and commercial perspectives. Primary inputs include structured interviews with laboratory directors, molecular pathologists, procurement leads, and clinical trial stakeholders, complemented by direct consultation with assay developers and platform providers. Secondary analysis encompassed peer-reviewed literature, regulatory guidance documents, technical whitepapers, and product manuals to validate analytical approaches and regulatory considerations. Where applicable, anonymized operational case studies from laboratories provided real-world context on workflow implementation and validation challenges.

Analytical rigor was maintained through methodical cross-validation of technology performance characteristics, sample handling protocols, and end-user requirements. The methodology prioritized peer-reviewed evidence and primary stakeholder testimony to ensure recommendations reflect both scientific validity and operational feasibility. Sensitivity to regional regulatory and reimbursement environments informed the regional insights, while supply chain assessments integrated procurement data and supplier interviews to evaluate vulnerability and mitigation options.

Limitations inherent to any synthesis are acknowledged, including variability in reporting standards across laboratories and differences in local regulatory interpretation. To address these constraints, the methodology emphasizes transparency in data sources, explicit documentation of assumptions, and the provision of methodological appendices that detail interview guides, inclusion criteria, and validation checkpoints. This approach enables stakeholders to adapt findings to their specific operational contexts with confidence in the underlying evidence base.

Integrated strategic conclusions on aligning technical capability, operational resilience, and collaborative partnerships to realize the full clinical potential of gene fusion testing

The maturation of gene fusion testing reflects a convergence of technological innovation, clinical necessity, and strategic alignment among diagnostic developers, health systems, and pharmaceutical partners. As sequencing-based approaches become more accessible and sample processing improves, the opportunity to embed robust fusion detection into routine diagnostics has never been clearer. However, realizing that potential requires deliberate investments in validated workflows, supply chain resilience, and collaborative evidence generation that demonstrates clinical utility across diverse patient populations.

Stakeholders that act now to align assay design with end-user workflows, diversify supply networks, and engage in strategic partnerships with therapy developers will be best positioned to capitalize on scientific advances while safeguarding operational continuity. The evolving regulatory and reimbursement landscape rewards clarity of evidence and cross-sector collaboration, making early engagement with clinical and regulatory stakeholders a competitive differentiator. In conclusion, the gene fusion testing ecosystem is poised for sustained clinical integration, and organizations that pursue coordinated technical, commercial, and operational strategies will lead the next phase of translation from discovery to improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of multiplex next-generation sequencing assays for simultaneous gene fusion detection in oncology patients
  • 5.2. Integration of liquid biopsy platforms for noninvasive detection of gene fusions in cancer screening programs
  • 5.3. Expansion of targeted therapies driving demand for precise gene fusion profiling in personalized medicine
  • 5.4. Development of AI-enabled bioinformatics pipelines to improve gene fusion identification accuracy in clinical diagnostics
  • 5.5. Growth of lab-developed tests offering rapid gene fusion analysis for point-of-care oncology decision support
  • 5.6. Rising collaborations between diagnostic companies and pharmaceutical firms to co-develop fusion-driven therapeutic biomarkers
  • 5.7. Regulatory approvals for novel gene fusion detection kits accelerating market entry across emerging geographies
  • 5.8. Increasing utilization of RNA-based multiplex PCR assays for comprehensive detection of rare fusion transcripts in solid tumors
  • 5.9. Emergence of automated sample-to-report platforms reducing turnaround time for gene fusion analysis in clinical labs
  • 5.10. Investment trends fueling expansion of decentralized testing networks for gene fusion assays in community hospitals

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Fusion Testing Market, by Technology

  • 8.1. Fluorescence In Situ Hybridization
  • 8.2. Immunohistochemistry
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Next Generation Sequencing
    • 8.3.2. Transcriptome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. Reverse Transcription Polymerase Chain Reaction

9. Gene Fusion Testing Market, by Sample Type

  • 9.1. Blood
    • 9.1.1. Plasma
    • 9.1.2. Serum
  • 9.2. Tissue
    • 9.2.1. Formalin Fixed Paraffin Embedded
    • 9.2.2. Fresh Frozen Tissue

10. Gene Fusion Testing Market, by Application

  • 10.1. Hematology
    • 10.1.1. Leukemia
    • 10.1.2. Lymphoma
  • 10.2. Oncology
    • 10.2.1. Breast Cancer
    • 10.2.2. Colorectal Cancer
    • 10.2.3. Lung Cancer
    • 10.2.4. Prostate Cancer
  • 10.3. Rare Diseases
    • 10.3.1. Developmental Disorders
    • 10.3.2. Neuromuscular Disorders

11. Gene Fusion Testing Market, by End User

  • 11.1. Diagnostic Laboratories
    • 11.1.1. Hospital Based Laboratories
    • 11.1.2. Independent Laboratories
  • 11.2. Hospitals
    • 11.2.1. Inpatient Facilities
    • 11.2.2. Outpatient Clinics
  • 11.3. Pharmaceutical Companies
    • 11.3.1. Biotechnology Companies
    • 11.3.2. Pharma Giants
  • 11.4. Research Institutions
    • 11.4.1. Academic Centers
    • 11.4.2. Private Research Laboratories

12. Gene Fusion Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Gene Fusion Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Gene Fusion Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.2. Illumina, Inc.
    • 15.3.3. F. Hoffmann-La Roche Ltd
    • 15.3.4. Agilent Technologies, Inc.
    • 15.3.5. QIAGEN N.V.
    • 15.3.6. Bio-Rad Laboratories, Inc.
    • 15.3.7. NanoString Technologies, Inc.
    • 15.3.8. BGI Genomics Co., Ltd.
    • 15.3.9. Foundation Medicine, Inc.
    • 15.3.10. Archer DX, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS GENE FUSION TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL GENE FUSION TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GENE FUSION TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. GENE FUSION TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GENE FUSION TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS GENE FUSION TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS GENE FUSION TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS GENE FUSION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY TECHNOL